Brooklyn ImmunoTherapeutics, Inc.
(NYSE Amex Equities : BTX)

( )
BTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -1.10%45.180.9%$1266.01m
JNJJohnson & Johnson -0.56%173.420.7%$1039.49m
AZNAstraZeneca Plc -0.61%57.311.0%$963.13m
LLYEli Lilly & Co. 2.56%262.531.1%$683.11m
ABBVAbbVie, Inc. -1.02%115.071.9%$660.94m
MRKMerck & Co., Inc. -1.24%75.460.7%$655.76m
BMYBristol-Myers Squibb Co. -1.24%68.451.0%$576.62m
GSKGlaxoSmithKline Plc -0.34%40.500.2%$160.71m
NRXPNRX Pharmaceuticals, Inc. -8.49%14.660.0%$158.90m
NVSNovartis AG -1.22%91.580.2%$158.06m
BYSIBeyondSpring, Inc. 176.01%26.580.0%$104.18m
NVONovo Nordisk A/S 5.49%98.240.1%$101.33m
RGENRepligen Corp. 1.41%252.596.8%$97.77m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 3.72%123.200.0%$87.25m
VTRSViatris, Inc. -3.03%13.760.0%$86.16m

Company Profile

Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.